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Abstract 
Background: Our knowledge of the incidence and prevalence of inflammatory bowel disease (IBD) is uncertain. 
Recent studies reported an increase in prevalence. However, they excluded a high proportion of ambiguous cases 
from general practice. Estimates are needed to inform health care providers who plan the provision of services for IBD 
patients. We aimed to estimate the IBD incidence and prevalence in UK general practice.
Methods: We undertook a retrospective cohort study of routine electronic health records from the IQVIA Medical 
Research Database covering 14 million patients. Adult patients from 2006 to 2016 were included. IBD was defined as 
an IBD related Read code or record of IBD specific medication. Annual incidence and 12‑month period prevalence 
were calculated.
Results: The prevalence of IBD increased between 2006 and 2016 from 106.2 (95% CI 105.2–107.3) to 142.1 (95% CI 
140.7–143.5) IBD cases per 10,000 patients which is a 33.8% increase. Incidence varied across the years. The incidence 
across the full study period was 69.5 (95% CI 68.6–70.4) per 100,000 person years.
Conclusions: In this large study we found higher estimates of IBD incidence and prevalence than previously 
reported. Estimates are highly dependent on definitions of disease and previously may have been underestimated.
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Background
Inflammatory bowel disease (IBD) includes a group 
of related, chronic relapsing disorders. They place sig-
nificant demand on healthcare resources including con-
sultation time, testing and treatment. In order to plan 
healthcare resources, knowledge of the size of the prob-
lem is required. This can be inferred from the incidence 
and prevalence of IBD in the population. A recent sys-
tematic review published in the Lancet assessed the 
incidence and prevalence of IBD around the world [1]. 
Studies using UK data from the 1990s reported incidence 
rates ranging from 21 to 32.2/100,000 [2–4] and preva-
lence estimates ranging from 328 to 409/100,000 [2, 5–7]. 
The review suggested that incidence rates have stabi-
lised in the western world, while other studies reported 
an ongoing increase in incidence rates [8, 9]. Two recent 
UK studies, that excluded a high proportion of ambigu-
ous diagnoses from general practice, reported consider-
ably higher prevalence estimates of 725–781/100,000 [10, 
11]. A third recent study reported estimates for ulcera-
tive colitis and Crohn’s disease but excluded cases of 
IBD unclassified (IBDU) [12]. However, IBD cannot be 
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classified in 20–30% of patients at first presentation and 
13% remain unclassified 1 year later [13]. This may have 
resulted in underestimates of the true IBD prevalence in 
UK general practice. Our aim is to establish estimates of 
incidence and prevalence of IBD in adult patients in UK 
general practice using routine primary care electronic 
health records.
UK primary care data, such as the IQVIA Medical 
Research Database (IMRD-UK) [formerly known as the 
Health Improvement Network (THIN)], are unique and 
particularly suitable for research. Over 95% of the UK 
population is registered with a GP [2, 14]. General prac-
titioner (GPs) act as gatekeepers to all services and spe-
cialists in secondary care (excluding emergency care). 
Patients are usually only registered with one GP at any 
one point in time; and for each patient the registration 
date and the date when the patient leaves the practice is 
known. This provides longitudinal data with known start 
and end date of follow-up. The role of the GP extends to 
the management of chronic patients.
The IMRD population is broadly representative of the 
UK population and prevalence of chronic diseases is 
comparable to national rates [15]. Findings can be gen-
eralised to the broader UK primary care population [15].
Methods
Data source
Study data consisted of electronic health care records 
available in the IMRD. The IMRD consists of anonymised, 
longitudinal individual level patient data from more than 
670 UK GP practices using the Vision practice software. 
In 2015 a total of over 14 million patients had contrib-
uted data to IMRD which reflects a coverage of about 
6% of the UK population [16]. Data are based on patient 
consultation information including symptoms, diagno-
ses, investigations and medications recorded as clini-
cal codes. Data were included into the study from GP 
practices from the date that the practice was deemed 
to be reporting all-cause mortality reliably compared to 
national statistics and from 1 year after the installation of 
the electronic medical record system. We applied these 
quality control measures to ensure data reliability and 
completeness.
The IMRD has received Research Ethics Commit-
tee approval by the NHS South-East Multicentre Ethics 
Committee for research as a whole. Scientific Review 
Committees (SRCs) have been established to review 
IMRD study protocols for scientific merit and feasibility. 
This project was given approval by the SRC (SRC Refer-
ence Number 17THIN089) on 23rd October 2017.
Study design and study population
We undertook a retrospective cohort study of patients 
with data in the IMRD who were at least 18 years of age 
during the period 1 January 2006 to 31 December 2016. 
The study cohort was dynamic with patients entering and 
exiting the study at different times. Patients entered the 
study 1 year after they registered with the GP practice or 
at age 18 years, whichever came later. Patients exited the 
study at the earliest of the following dates: deregistration 
with the practice; death; or 1 January 2017.
Definition of IBD diagnosis
The outcome of interest was newly diagnosed IBD. We 
searched the medical records of the study population 
for patients with a diagnosis of IBD. Those with a clini-
cal code indicative of IBD and/or at least one prescrip-
tion of an IBD specific medication in the patient record 
were classified as cases of IBD. The date of IBD diagno-
sis was taken as the first occurrence of a clinical code 
for IBD or first prescription of IBD specific medication 
in the patient record. We were interested in the broad 
category of inflammatory bowel disease and included 
clinical codes for general IBD, ulcerative colitis, Crohn’s 
disease, indeterminate colitis and microscopic colitis. 
Clinical code lists were adapted from those used in pre-
vious literature [6, 17]. IBD specific medication included 
mesalazine, olsalazine and balsalazide. Sulfasalazine, 
prednisolone and budesonide preparations were consid-
ered IBD specific if rectal. Preparations of beclometasone 
needed to clearly specify use for the bowel to be included. 
Therefore, the definitions for medications were purpose-
fully narrow and decisions on inclusion were exclusive if 
in doubt. The complete code list to identify IBD diagno-
ses is available in Additional file 1.
Analysis
The annual incidence and 12-month period prevalence 
of IBD were determined for 2006–2016 considering all 
adult patients contributing data to IMRD in that period. 
Annual incidence was defined as the number of new 
cases of IBD during a 1  year period over the total time 
each patient was observed (person-time at risk). Period 
prevalence was defined as new and pre-existing IBD cases 
during a 12-month period over the number of patients in 
the IMRD database during the same time period. Con-
fidence intervals for incidence rates were exact Poisson 
confidence limits. Confidence intervals for prevalence 
were calculated using the Wilson procedure for propor-
tions without a correction for continuity. Incidence rates 
for male and female patients were compared using the 
two sample z test.
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All analyses were undertaken in R version 3.6.1 
(Vienna, Austria) [18]. The package “epitools” was used 
to calculate exact confidence intervals for incidence rates 




We retrieved 6,965,853 records of adult patients from 
the IMRD database and excluded 33,730 patients who 
entered the study after the study period (Fig.  1). We 
included a total of 6,932,123 patients in the analysis 
of IBD prevalence. The prevalence of IBD increased 
between 2006 and 2016 from 106.2 (95% CI 105.2–107.3) 
to 142.1 (95% CI 140.7–143.5) IBD cases per 10,000 in the 
adult IMRD population with an average increase of 2.96% 
per annum. This amounts to an increase of 33.8% from 
2006 to 2016. More women than men had a recorded 
diagnosis of IBD (Fig. 2).
We excluded 61,125 prevalent IBD cases from the 
dataset which resulted in a dataset of 6,870,998 patients 
for the analysis of IBD incidence (Fig.  1). There were 
25,470 IBD incidence cases between 2006 and 2016. 
4736 (18.6%) had an IBD Read code only, 9632 (37.8%) 
had a prescription of an IBD medication only and 11,102 
(43.6%) had both. Incidence of IBD in the adult IMRD 
population varied across the years with a maximum of 
76.4 (95% CI 73.6–79.4) per 100,000 recorded in 2010 
and the lowest incidence of 63.5 (95% CI 60.4–66.7) per 
100,000 recorded in 2016 (Fig.  3). The incidence across 
the full study period was 69.5 (95% CI 68.6–70.4) per 
100,000 person years. The incidence rate was higher 
in women than men for the study period (73.09 versus 
65.83, z = 8.3, p < 0.0001).
Discussion
Summary of study findings
The analyses of IBD prevalence and incidence included 
a total of 6,932,123 and 6,870,998 adult patients, respec-
tively. The prevalence of IBD in 2016 was 142.1 (95% CI 
140.7–143.5) per 10,000 adult patients. The prevalence 
of IBD increased between 2006 and 2016 by 33.8%. This 
is likely due to the fact that IBD is a chronic condition 
which is associated with a low mortality rate. The mean 
IBD incidence for the study period was 69.3 (95% CI 
66.8–71.8) per 100,000 person years. The drop in inci-
dence between 2010 and 2011 may be an artefact or 
caused by an administrative change in coding/reporting 
standards. Over the most recent 5-year period, the inci-
dence of IBD was relatively stable.
Study strengths and limitations
The IQVIA Medical Research database is a rich source of 
routine electronic health care records of patients man-
aged in primary care and is particularly useful for the 
study of real world problems. The study population was 
Fig. 1 Overview of inclusion and exclusion of cases for the analyses of IBD incidence and prevalence
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large and covered nearly 50% of all UK Clinical Commis-
sioning Groups [16] meaning that findings are generalis-
able to UK primary care in general.
The criterion “registration date plus 1  year” to assess 
patients’ eligibility for study inclusion avoided the sys-
tematic over-reporting of incidence rates in the first year 
of follow-up for newly registered patients [21]. It also 
Fig. 2 12‑month period prevalence of IBD per 10,000 adult IMRD population
Fig. 3 Annual IBD incidence per 100,000 person‑years in the adult IMRD population
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prevented the double counting of prevalent cases when 
patients transfer from one IMRD practice to another.
Limitations that might have affected the research are 
linked to characteristics of routine data.
IBD diagnoses might be missing either due to incor-
rect coding, missed coding or recording as free-text. This 
might have led to an underestimation of IBD incidence 
and prevalence. However, we included a record of an IBD 
specific medication in the definition of an IBD diagnosis 
which mitigated the effect. This may explain our higher 
figures for IBD incidence and prevalence when compared 
to a recent study which only included patients with two 
IBD Read codes recorded or one IBD Read code and an 
IBD drug code [11].
Potential misclassification through miscoding of ulcer-
ative colitis as Crohn’s disease and vice versa, or by using 
higher order codes rather than disease specific codes was 
of no consequence to our study. We were interested in 
the broad category of inflammatory bowel disease rather 
than sub-category, severity or location of disease. We 
were able to include codes for IBD and indeterminate 
IBD and present the complete picture of IBD in primary 
care which is in contrast to a recent study which only 
focused on patients with a diagnosis of ulcerative colitis 
or Crohn’s disease [12].
A limitation of our study may be our inability to ver-
ify IBD cases. While we mitigated against under-coding, 
over-coding is a possibility. A study reported that about 
6% of IBD codes did probably not relate to a true IBD 
diagnosis [6]. However, the study relied on confirmatory 
data from GP questionnaires and considered coded data 
from 20 years ago.
Findings in the context of existing literature
Published figures on UK IBD incidence rates range from 
21 to 37.5/100,000 [2–4, 10–12]. Studies consistently 
report that prevalence is rising worldwide because of 
the low mortality associated with this chronic condition. 
UK prevalence estimates range from 328/100,000 in the 
1990s [6] to 970/100,000 in 2017 [12].
Our estimates of incidence and prevalence of IBD in 
the UK are about 1.8 and 1.5 times higher than the most 
recent estimates. Published studies are very heterogene-
ous, complicating comparison of reported rates across 
studies. Major variations that explain at least some of the 
differences include: (1) our study included adult patients 
only, while the majority of other studies covered a wider 
age range including children. This impacts the incidence 
and prevalence rates of IBD which has an onset that 
peaks in adulthood. (2) Improvements in diagnostic tech-
nology now enable the detection of milder cases [9]. (3) 
Some smaller studies used GP records to identify cases 
with subsequent exclusion of unverified cases. Exclusions 
ranged from 8 to 26% of patients [2, 3, 10]. This could 
have underestimated true IBD prevalence. (4) Studies 
used different definitions of disease. A number of stud-
ies did not include indeterminate IBD or microscopic 
IBD in their definition. A recent study reported the inci-
dence and prevalence of ulcerative colitis and Crohn’s 
disease in the IMRD-UK database [12]. The study only 
included Read codes for Crohn’s disease and ulcerative 
colitis in the definition of disease. In contrast we used 
a very comprehensive and sensitive list of Read codes 
and drug codes (48 codes) for the identification of IBD, 
ulcerative colitis, Crohn’s disease, indeterminate IBD and 
microscopic colitis. In addition, a previous study using 
the IMRD-UK data used a similar list of Read codes to 
our study for the identification of IBD. However, they 
included non-specific IBD medications to identify IBD 
cases and only included patients with at least two sub-
sequent IBD records or an IBD record and a recorded 
prescription of an IBD related drug [11]. According to 
our data, this approach may have missed at least 37.8% 
of cases. We were able to increase the sensitivity of our 
Read code list by using medications to identify additional 
IBD cases because we restricted inclusion of prescrip-
tions to IBD specific medications. This is an advantage of 
our study over these two recent IMRD-UK studies.
Implications for research and practice
Taken together, the evidence suggests that the IBD inci-
dence and prevalence in the UK adult population may 
be higher than the latest published figures. Some of the 
differences in reported rates may be due to differences 
in methodology including differences in methods of case 
definition [22]. Case definition is complicated by the fact 
that IBD is a heterogeneous group of disorders. Crohn’s 
disease and ulcerative colitis are considered as the two 
extremes of a spectrum of chronic gut disorders [23]. 
Furthermore, the phenotype of IBD is not uniform result-
ing in IBD unclassified cases [13, 24]. The overlap with 
other infectious, inflammatory and autoimmune disor-
ders led to suggestions to diverge from the classification 
of IBD into ulcerative colitis and Crohn’s disease and to 
reclassify IBD considering a broader disease spectrum 
[25]. This argues for a broader definition of IBD in the 
estimation of IBD incidence and prevalence.
Conclusions
In this large study we found higher estimates of IBD 
incidence and prevalence than previously reported. Esti-
mates are highly dependent on definitions of disease and 
previously may have been underestimated. We believe 
that our sensitive approach to identifying IBD cases may 
be more reflective of the true burden of disease in UK 
Page 6 of 7Freeman et al. BMC Gastroenterol          (2021) 21:139 
general practice. Health care providers who plan ser-
vices for IBD patients need to make allowances for these 
updated figures and should consider the definition of dis-
ease in published studies.
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